A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer (Q33401816)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer |
scientific article |
Statements
1 reference
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer (English)
1 reference
H L Kindler
1 reference
D A Richards
1 reference
L E Garbo
1 reference
E B Garon
1 reference
J J Stephenson
1 reference
C M Rocha-Lima
1 reference
H Safran
1 reference
D Chan
1 reference
D M Kocs
1 reference
F Galimi
1 reference
J McGreivy
1 reference
S L Bray
1 reference
Y Hei
1 reference
E G Feigal
1 reference
E Loh
1 reference
C S Fuchs
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference